ArticleApplied microbiology and biotechnology2026
Enhancing foot-and-mouth disease virus thermostability with a VP1 substitution selected by host HSP60 inhibition.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foot-and-mouth disease virus (FMDV) exhibits greater temperature sensitivity compared to many other picornaviruses, which poses a substantial challenge for the stability of inactivated vaccines. Therefore, enhancing the thermal stability of the FMDV capsid is crucial. FMDV exists as a quasispecies with high mutation rates, providing a basis for selection under pressure. Our group previously discovered that heat shock protein HSP60 was recruited to support FMDV replication by promoting the assembly of the viral replication complex (RC). By applying the HSP60 inhibitor mizoribine, we selected FMDV variants with enhanced fitness under conditions of impaired HSP60 function. Subsequent sequencing of the selected populations and reverse genetics approaches identified a key amino acid substitution, T171P in the viral VP1 protein that confers resistance to the HSP60 inhibitor. Structural simulation predicted that the T171P substitution enhances the stability of the VP1 protein, which was further supported by experimental evidence demonstrating increased thermal stability of the whole viral capsid. A series of experiments, including virion stability assessment using the PaSTRy assay, quantification of intact particles following heat challenge, and evaluation of viral infectivity at elevated temperatures, demonstrated that the T171P-VP1 variant possesses enhanced thermostability compared to the wild-type (WT) virus. Furthermore, immunization experiments showed that the inactivated T171P-VP1 variant, after heat challenge, elicited a stronger neutralizing antibody response than the similarly treated WT virus. This study identifies a novel amino acid substitution that significantly enhances FMDV thermostability. This finding not only provides a viable strategy for improving the thermal stability of FMD vaccines but also opens new avenues for exploring the intricate mechanisms of host-virus interaction. KEY POINTS: • A novel HSP60 inhibitor-based selection strategy identified the T171P-VP1 substitution conferring enhanced viral fitness. • The T171P substitution significantly improves FMDV capsid thermostability compared to the wild-type virus. • The inactivated T171P-VP1 variant induces stronger neutralizing antibody responses after heat challenge, offering a promising approach for thermostable FMD vaccine development.
Indexed as
Identifiers
42909628What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.